August 11th, 2010 Indolent systemic mastocytosis has a low disease progression rate, normal life expectancy in most adults
Indolent systemic mastocytosis is a group of rare diseases for which reliable predictors of progression and outcome are still lacking. Analysis showed that serum beta2-microglobulin and mast/stem cell growth factor receptor gene (KIT) mutation in mast cells plus myeloid and lymphoid hematopoietic lineages was the best combination for predicting disease progression. Mast cells
